🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

8-year outcomes of enzalutamide vs a non-steroidal anti-androgen for metastatic, hormone-sensitive #ProstateCancer (ENZAMET; ANZUP 1304). Presented by Alison Zhang, MD, PhD University of Sydney. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4dU867V ASCO

177Lu-PSMA-617 consolidation therapy post docetaxel in patients with de-novo high-volume #mHSPC: a randomized, phase 2 trial. Presentation by Ashwani Sood, MBBS, DRM, DNB. #ASCO25 written coverage by Rashid K. Sayyid > bit.ly/3HmssdT ASCO

Real-world patient characteristics, treatment patterns, and overall survival in #mHSPC: Insights by PTEN status. Presentation by Dana Rathkopf Memorial Sloan Kettering Cancer Center. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4jz9pKS ASCO

Trials-in-progress: Mevrometostat in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with #mCRPC: The phase 3, randomized #MEVPRO-2 study. Presentation by Neal Shore, MD, FACS CURC. #ASCO25 written coverage by Rashid K. Sayyid USC >

A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with #mCRPC (CA071-1000 - rechARge). Presentation by Kim Chi, MD Vancouver Prostate Centre. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4dKQMST ASCO

Efficacy and safety of second-line cabozantinib +/ atezolizumab for patients with advanced #RCC after progression on immuno-oncology combinations: subgroup analysis of #CONTACT03. Presented by Cristina Suárez, MD, PhD Vall d’Hebron Institute of Oncology (VHIO). #ASCO25 written coverage by Rashid K. Sayyid USC >

Neoadjuvant lenvatinib + pembrolizumab for resectable clear-cell #RenalCellCarcinoma (PELUR): A prospective phase 2 study. Presentation by Zhu Shimiao, MD, PhD. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/43z3VJO ASCO

ctDNA monitoring in patients with advanced #UrothelialCarcinoma treated with enfortumab vedotin +/- pembrolizumab. Presentation by Kevin Reyes UC San Francisco. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/3HpPTTy ASCO

MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle-invasive #BladderCancer undergoing radical cystectomy. Presentation by Lawrence Schwartz, MD Memorial Sloan Kettering Cancer Center. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/43rDUxr ASCO

EV-103 Cohort H: neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with #MIBC – 3-year efficacy results. Presentation by Nataliya Mar UC Irvine. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4n2ANUz ASCO

First survival outcomes and biomarker results of #SURE01: neoadjuvant sacituzumab govitecan monotherapy, followed by radical cystectomy, in patients with muscle-invasive urothelial bladder cancer. Presentation by Brigida Maiorano. #ASCO25 written coverage by Rashid K. Sayyid >

A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive #NMIBC: ssantrop (apro07-2022). Presentation by joaquim bellmunt Dana-Farber. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4jzkbAM

Trials-in-Progress – #PUNCH03: A phase II study of disitamab vedotin combined with tislelizumab and BCG in HER2-positive high-risk #NMIBC. Presentation by Zongren Wang. #ASCO25 written coverage > bit.ly/43XOg8i Rashid K. Sayyid

Trials-in-progress – sasanlimab as bladder-sparing maintenance treatment after neoadjuvant chemotherapy in patients with MIBC: The phase 2, SASAN-SPARING trial. Presentation by Elena Sevillano M.D. PhD. #ASCO25 written coverage by Rashid K. Sayyid > bit.ly/3SC4r4S

Trials-in-Progress – Intravesical sacituzumab tirumotecan in participants with intermediate-risk #NMIBC: The phase 1/2 #TroFuse027 study. Presented by Joshua Meeks NM Urology. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4dMVaRk ASCO

ABLE-22: safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy in BCG-unresponsive #NMIBC—a randomized, open-label, phase 2 study. Presented by Sia Daneshmand, M.D. Keck Medicine of USC. #ASCO25 written coverage by Rashid K. Sayyid

Radioligand therapies in #ProstateCancer: Hits, misses, and next steps. Presentation by Jorge Garcia, MD, PhD. #ASCO25 written coverage by Rashid K. Sayyid > bit.ly/43Q9nbC ASCO

Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive #ProstateCancer (3BULLSEYE Trial). Presented by Bastiaan M. Privé, MD, PhD Radboudumc. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4kTFrCk

#BULLSEYE Discussion: Radioligand Therapies Unplugged: Is it time to break up with androgen deprivation therapy? Presented by Atish Choudhury, MD PhD Dana-Farber. #ASCO25 written coverage by Rashid K. Sayyid USC > bit.ly/4411stc ASCO

ESMO 2024 Quick Take Insights: Prostate Cancer - #ARANOTE: Darolutamide + ADT shows significant rPFS benefits in mHSPC, offering a new treatment without docetaxel. - #PEACE3Study: Radium-223 + enzalutamide in mCRPC enhances rPFS & OS when used with bone protection in patients